Blockade of individual notch ligands and receptors controls graft-versus-host disease

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1590-1604

  Tran, Ivy T ^a   Sandy, Ashley R ^a,b   Carulli, Alexis J ^c   Ebens, Christen ^a,d   Chung, Jooho ^a,e   Shan, Gloria T ^a   Radojcic, Vedran ^a,f   Friedman, Ann ^a   Gridley, Thomas ^g   Shelton, Amy ^h   Reddy, Pavan ^f   Samuelson, Linda C ^c,f   Yan, Minhong ^h   Siebel, Christian W ^h   Maillard, Ivan ^a,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Immunology Program   (United States)

^c Integrative of Physiology   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e Cellular and Molecular Biology Graduate Program   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g Maine Medical Center Research Institute   (United States)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; INTESTINAL TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TOXICITY;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; DIARRHEA; DIBENZAZEPINES; GRAFT VS HOST DISEASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-2; INTESTINES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; REGENERATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875837518     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65477     Document Type: Article

References (75)

1. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170.
2. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006;90:133-173.
3. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383.
4. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352.
5. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versushost disease. Lancet. 2009;373(9674):1550-1561.
6. Chao NJ, Chen BJ. Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol. 2006;43(1):32-41.
7. Zeiser R, Beilhack A, Negrin RS. Acute graft-versushost disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther. 2006;1(2):203-212.
8. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192-3204.
9. Zhang Y, et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graftversus-host disease. Blood. 2011;117(1):299-308.
10. Kopan R, Ilagan MX. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell. 2009;137(2):216-233.
11. Louvi A, Artavanis-Tsakonas S. Notch and disease: A growing field. Semin Cell Dev Biol. 2012; 23(4):473-480.
12. Radtke F, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10(5):547-558.
13. Sambandam A, et al. Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol. 2005;6(7):663-670.
14. Tan JB, Visan I, Yuan JS, Guidos CJ. Requirement for Notch1 signals at sequential early stages of intrathymic T cell development. Nat Immunol. 2005;6(7):671-679.
15. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17(6):749-756.
16. Osborne BA, Minter LM. Notch signalling during peripheral T-cell activation and differentiation. Nat Rev Immunol. 2007;7(1):64-75.
17. Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol. 2009;9(2):116-124.
18. Maillard I, Fang T, Pear WS. Regulation of lymphoid development, differentiation and function by the Notch pathway. Annu Rev Immunol. 2005;23:945-974.
19. Radtke F, Fasnacht N, Macdonald HR. Notch Signaling in the immune system. Immunity. 2010;32(1):14-27.
20. Tu L, et al. Notch signaling is an important regulator of type 2 immunity. J Exp Med. 2005; 202(8):1037-1042.
21. Maillard I, et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood. 2004;104(6):1696-1702.
22. Weng AP, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003;23(2):655-664.
23. Maillard I, et al. Canonical Notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2(4):356-366.
24. Wu Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010; 464(7291):1052-1057.
25. Ridgway J, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083-1087.
26. Wolfe MS. gamma-Secretase in biology and medicine. Semin Cell Dev Biol. 2009;20(2):219-224.
27. Riccio O, et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008;9(4):377-383.
28. Van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959-963.
29. Saito T, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity. 2003;18(5):675-685.
30. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigenpresenting cells. Cell. 2004;117(4):515-526.
31. Ladi E, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170(6):983-992.
32. Koch U, et al. Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J Exp Med. 2008;205(11):2515- 2523.
33. Hozumi K, et al. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol. 2004;5(6):638-644.
34. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A. 2005;102(14):5126-5131.
35. Bernstein ID, Boyd RL, Van Den Brink MR. Clinical strategies to enhance posttransplant immune reconstitution. Biol Blood Marrow Transplant. 2008;14(1 suppl 1):94-99.
36. Na IK, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versushost disease. J Clin Invest. 2010;120(1):343-356.
37. Albi N, et al. Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation. Blood. 1996;87(9):3993-4000.
38. Aversa F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193.
39. Hsu KC, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-4884.
40. Venstrom JM, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805-816.
41. Weisdorf D, et al. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant. 2011;18(6):937-943.
42. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med. 1971;134(6):1513-1528.
43. Cudkowicz G, Stimpfling JH. Induction of immunity and of unresponsiveness to parental marrow grafts in adult F-1 hybrid mice. Nature. 1964;204:450-453.
44. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol. 1977;7(9):655-663.
45. Dennert G, Anderson CG, Warner J. T killer cells play a role in allogeneic bone marrow graft rejection but not in hybrid resistance. J Immunol. 1985;135(6):3729-3734.
46. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol. 2005;6(9):938-945.
47. Patel R, Belanger S, Tai LH, Troke AD, Makrigiannis AP. Effect of Ly49 haplotype variance on NK cell function and education. J Immunol. 2010;185(8):4783-4792.
48. Amsen D, et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity. 2007;27(1):89-99.
49. Tacchini-Cottier F, Allenbach C, Otten LA, Radtke F. Notch1 expression on T cells is not required for CD4+ T helper differentiation. Eur J Immunol. 2004;34(6):1588-1596.
50. Tacchini-Cottier F, et al. An immunomodulatory function for neutrophils during the induction of a CD4(+) Th2 response in BALB/c mice infected with Leishmania major. J Immunol. 2000;165(5):2628-2636.
51. Noguera-Troise I, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032-1037.
52. Visan I, Tan JB, Yuan JS, Harper JA, Koch U, Guidos CJ. Regulation of T lymphopoiesis by Notch1 and Lunatic fringe-mediated competition for intrathymic niches. Nat Immunol. 2006;7(6):634-643.
53. Besseyrias V, et al. Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation. J Exp Med. 2007;204(2):331-343.
54. Hoyne GF, et al. Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol. 2000;12(2):177-185.
55. Yvon ES, et al. Over expression of the Notch ligand, Jagged-1 induces alloantigen-specific human regulatory T cells. Blood. 2003;102(10):3815-3821.
56. Wong KK, et al. Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J Clin Invest. 2003;112(11):1741-1750.
57. Riella LV, et al. Blockade of Notch ligand delta1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation. J Immunol. 2011;187(9):4629-4638.
58. Kijima M, et al. Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction. Proc Natl Acad Sci U S A. 2008;105(19):7010-7015.
59. Ruggeri L, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339.
60. Velardi A, Ruggeri L, Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol. 2012;19(4):319-323.
61. Vandussen KL, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139(3):488-497.
62. Cullion K, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood. 2009;113(24):6172-6181.
63. Real PJ, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-58.
64. Pellegrinet L, et al. Dll1-and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology. 2011;140(4):1230-1240.
65. Gao J, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell. 2009;4(6):548-558.
66. Varnum-Finney B, Halasz LM, Sun M, Gridley T, Radtke F, Bernstein ID. Notch2 governs the rate of generation of mouse long-and shortterm repopulating stem cells. J Clin Invest. 2011; 121(3):1207-1216.
67. Klinakis A, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-233.
68. Liu Z, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest. 2011;121(2):800-808.
69. Yan M, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7282):E6-7.
70. Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004;269(1):81-94.
71. Mccright B, Lozier J, Gridley T. Generation of new Notch2 mutant alleles. Genesis. 2006;44(1):29-33.
72. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001; 98(12):3456-3464.
73. Cooke KR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
74. Zakrzewski JL, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006;12(9):1039-1047.
75. Lopez-Diaz L, et al. Parietal cell hyperstimulation and autoimmune gastritis in cholera toxin transgenic mice. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G970-G979.